Evidence map›Paper›PMID 31421683›Full record

ArticleAlzheimer's research & therapy2019

Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI.

Paula M Petrone, Adrià Casamitjana, Carles Falcon, Miquel Artigues, Grégory Operto, Raffaele Cacciaglia, José Luis Molinuevo, Verónica Vilaplana, Juan Domingo Gispert, Alzheimer’s Disease Neuroimaging Initiative

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Tracking early cognitive decline in preclinical AD with brain MRI similarity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Deep Learning-Based Prediction of PET Amyloid Status Using MRI.AJNR. American journal of neuroradiology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Deformation-based morphometry: a sensitive imaging approach to detect radiation-induced brain injury?Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Article
  9. Review
  10. Article
  11. Predicting amyloid-beta pathology in the general population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Biomarker testing in MCI patients-deciding who to test.Alzheimer's research & therapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Paula M PetroneBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, C/ Wellington 30, 08005, Barcelona, Spain.
Adrià CasamitjanaDepartment of Signal Theory and Communications, Universitat Politècnica de Catalunya, C/ Jordi Girona 1-3, edifici D5 Campus Nord UPC, 08034, Barcelona, Spain.
Carles FalconBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, C/ Wellington 30, 08005, Barcelona, Spain.
Miquel ArtiguesDepartment of Signal Theory and Communications, Universitat Politècnica de Catalunya, C/ Jordi Girona 1-3, edifici D5 Campus Nord UPC, 08034, Barcelona, Spain.
Grégory OpertoBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, C/ Wellington 30, 08005, Barcelona, Spain.
Raffaele CacciagliaBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, C/ Wellington 30, 08005, Barcelona, Spain.
José Luis MolinuevoBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, C/ Wellington 30, 08005, Barcelona, Spain.
Verónica VilaplanaDepartment of Signal Theory and Communications, Universitat Politècnica de Catalunya, C/ Jordi Girona 1-3, edifici D5 Campus Nord UPC, 08034, Barcelona, Spain. veronica.vilaplana@upc.edu.
Juan Domingo GispertBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, C/ Wellington 30, 08005, Barcelona, Spain. jdgispert@barcelonabeta.org.
Alzheimer’s Disease Neuroimaging Initiative
Pasqual Maragall Foundation · ESUniversitat Pompeu Fabra · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable · ES

Funding

European Regional Development Fund MALEGRA TEC2016-75976-RMinisterio de Economía, Industria y Competitividad, Gobierno de España MALEGRA TEC2016-75976-RMinisterio de Economía, Industria y Competitividad, Gobierno de España RYC-2013-13054Ministerio de Educación, CUltura y Deporte FPU
6 · The paper itself

Abstract

backgroundMagnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer's disease (AD) pathophysiologic continuum constituting what has been established as "AD signature". To what extent MRI can detect amyloid-related cerebral changes from structural MRI in cognitively unimpaired individuals is still an area open for exploration.

methodLongitudinal 3D-T1 MRI scans were acquired from a subset of the ADNI cohort comprising 403 subjects: 79 controls (Ctrls), 50 preclinical AD (PreAD), and 274 MCI and dementia due to AD (MCI/AD). Amyloid CSF was used as gold-standard measure with established cutoffs (< 192 pg/mL) to establish diagnostic categories. Cognitively unimpaired individuals were defined as Ctrls if were amyloid negative and PreAD otherwise. The MCI/AD group was amyloid positive. Only subjects with the same diagnostic category at baseline and follow-up visits were considered for the study. Longitudinal morphometric analysis was performed using SPM12 to calculate Jacobian determinant maps. Statistical analysis was carried out on these Jacobian maps to identify structural changes that were significantly different between diagnostic categories. A machine learning classifier was applied on Jacobian determinant maps to predict the presence of abnormal amyloid levels in cognitively unimpaired individuals. The performance of this classifier was evaluated using receiver operating characteristic curve analysis and as a function of the follow-up time between MRI scans. We applied a cost function to assess the benefit of using this classifier in the triaging of individuals in a clinical trial-recruitment setting.

resultsThe optimal follow-up time for classification of Ctrls vs PreAD was Δt > 2.5 years, and hence, only subjects within this temporal span are used for evaluation (15 Ctrls, 10 PreAD). The longitudinal voxel-based classifier achieved an AUC = 0.87 (95%CI 0.72-0.97). The brain regions that showed the highest discriminative power to detect amyloid abnormalities were the medial, inferior, and lateral temporal lobes; precuneus; caudate heads; basal forebrain; and lateral ventricles.

conclusionsOur work supports that machine learning applied to longitudinal brain volumetric changes can be used to predict, with high precision, the presence of amyloid abnormalities in cognitively unimpaired subjects. Used as a triaging method to identify a fixed number of amyloid-positive individuals, this longitudinal voxel-wise classifier is expected to avoid 55% of unnecessary CSF and/or PET scans and reduce economic cost by 40%.

Indexed as

AgedAlzheimer DiseaseAmyloid beta-PeptidesBrainCognitive DysfunctionFemaleHumansLongitudinal StudiesMachine LearningMagnetic Resonance ImagingMaleROC CurveAmyloid beta-PeptidesJacobian determinantLongitudinal voxel-wise analysisMachine learningMRIPreclinical AD signature

Identifiers

PMID31421683
PMCPMC6698344
OpenAlexW2968364625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.